First Tracks Biotherapeutics, Inc. (TRAX)
45.89
+2.41
(+5.54%)
USD |
NASDAQ |
Oct 27, 14:12
First Tracks Biotherapeutics Enterprise Value : 1.375B for Oct. 26, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 26, 2026 | 1.375B |
| October 23, 2026 | 1.395B |
| October 22, 2026 | 1.363B |
| October 21, 2026 | 1.350B |
| October 20, 2026 | 1.296B |
| October 19, 2026 | 1.120B |
| October 16, 2026 | 1.056B |
| October 15, 2026 | 1.112B |
| October 14, 2026 | 1.044B |
| October 13, 2026 | 957.49M |
| October 12, 2026 | 1.041B |
| October 09, 2026 | 963.51M |
| October 08, 2026 | 969.17M |
| October 07, 2026 | 918.92M |
| October 06, 2026 | 947.23M |
| October 05, 2026 | 1.004B |
| October 02, 2026 | 1.014B |
| October 01, 2026 | 1.037B |
| September 30, 2026 | 1.091B |
| September 29, 2026 | 1.110B |
| September 28, 2026 | 1.133B |
| September 25, 2026 | 1.054B |
| September 24, 2026 | 1.104B |
| September 23, 2026 | 1.134B |
| September 22, 2026 | 1.288B |
| Date | Value |
|---|---|
| September 21, 2026 | 1.216B |
| September 18, 2026 | 1.202B |
| September 17, 2026 | 1.224B |
| September 16, 2026 | 1.217B |
| September 15, 2026 | 1.198B |
| September 14, 2026 | 1.166B |
| September 11, 2026 | 1.126B |
| September 10, 2026 | 1.180B |
| September 09, 2026 | 1.237B |
| September 08, 2026 | 1.316B |
| September 04, 2026 | 1.268B |
| September 03, 2026 | 1.341B |
| September 02, 2026 | 1.439B |
| September 01, 2026 | 1.293B |
| August 31, 2026 | 1.317B |
| August 28, 2026 | 1.318B |
| August 27, 2026 | 1.420B |
| August 26, 2026 | 1.400B |
| August 25, 2026 | 1.433B |
| August 24, 2026 | 1.368B |
| August 21, 2026 | 1.362B |
| August 20, 2026 | 1.319B |
| August 19, 2026 | 1.447B |
| August 18, 2026 | 1.389B |
| August 17, 2026 | 1.379B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AnaptysBio, Inc. | 1.555B |
| Mirum Pharmaceuticals, Inc. | 5.717B |
| Biogen, Inc. | 44.33B |
| Immunovant, Inc. | 5.013B |
| Forte Biosciences, Inc. | 1.378B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -33.37M |
| Total Expenses (Quarterly) | 33.37M |
| EPS Diluted (Quarterly) | -0.943 |
| Earnings Yield | -10.77% |
| Normalized Earnings Yield | -10.77 |